JRCT ID: jRCTs051180115
Registered date:11/03/2019
TACE + vitamin K treatment
Basic Information
| Recruitment status | Complete |
|---|---|
| Health condition(s) or Problem(s) studied | Hepatocellular carcinoma (HCC) |
| Date of first enrollment | 19/04/2017 |
| Target sample size | 200 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | daily dosing of vitamin K2(45mg) since one day before TACE to 28 days after |
Outcome(s)
| Primary Outcome | treatment effect of TACE |
|---|---|
| Secondary Outcome | Safety |
Key inclusion & exclusion criteria
| Age minimum | >= 18age old |
|---|---|
| Age maximum | <= 85age old |
| Gender | Both |
| Include criteria | Patients indicated to transarterial chemoembolization (TACE) against hepatocellular carcinoma, ECOG PS 0 or 1, Child-Pugh score 5-7, obtained written informed consent |
| Exclude criteria | Patients who underwent previous TACE greater than twice, patients with warfarin dosing, patients who have been given vitamin K before the enrollment |
Related Information
| Primary Sponsor | Haruna Yoshimichi |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Yoshimichi Haruna |
| Address | 3-1-56 Bandaihigashi Sumiyoshi-ku Osaka, Japan Osaka Japan 558-8558 |
| Telephone | +81-6-6692-1201 |
| apple-123-grape@ab.auone-net.jp | |
| Affiliation | 3-1-56 Bandaihigashi Sumiyoshi-ku Osaka, Japan |
| Scientific contact | |
| Name | Yoshimichi Haruna |
| Address | 3-1-56 Bandaihigashi Sumiyoshi-ku Osaka, Japan Osaka Japan 558-8558 |
| Telephone | +81-6-6692-1201 |
| apple-123-grape@ab.auone-net.jp | |
| Affiliation | Osaka General Medical Center |